To investigate the efficacy of HER2-targeted therapy in colon cancer cells harboring HER2 G776S, we examined the effect of treatment with afatinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI). This evidence concerns the gene ERBB2 and malignant colon neoplasm.